KRAS(G12C) inhibition using MRTX1257: a novel radio-sensitizing partner

BACKGROUND: KRAS activating mutations are considered the most frequent oncogenic drivers and are correlated with radio-resistance in multiple cancers including non-small cell lung cancer (NSCLC) and colorectal cancer. Although KRAS was considered undruggable until recently, several KRAS inhibitors h...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurent, Pierre-Antoine, Milic, Marina, Quevrin, Clément, Meziani, Lydia, Liu, Winchygn, Morel, Daphné, Signolle, Nicolas, Clémenson, Céline, Levy, Antonin, Mondini, Michele, Deutsch, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619254/
https://www.ncbi.nlm.nih.gov/pubmed/37907934
http://dx.doi.org/10.1186/s12967-023-04619-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619254/
https://www.ncbi.nlm.nih.gov/pubmed/37907934
http://dx.doi.org/10.1186/s12967-023-04619-0

Ejemplares similares